RxDoctor Payments Data

Howard Adler, MD

Medical Oncology · Delray Beach, FLNPI 1427006782

Payments from drug & device makers

$21,059in general payments, 2019–2025

Across 309 payments — averaging $68.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$15K
  • Takeda Pharmaceuticals U.S.A., Inc.$884
  • Johnson & Johnson$633
  • Novartis$487
  • AstraZeneca$426
  • Merck$372
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$5,45393%
  • Education$3987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$21,059 in reported general payments places this provider in the 50th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$163,337
Medicare patients
669
Services billed
2,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide37$720,882
CalquenceAcalabrutinib Maleate44$608,824
ImbruvicaIbrutinib29$571,371
BrukinsaZanubrutinib45$567,733
VenclextaVenetoclax43$534,537
Lenalidomide29$378,752
JakafiRuxolitinib Phosphate24$361,777
OjjaaraMomelotinib Dihydrochloride12$343,399
ScemblixAsciminib Hydrochloride12$246,039
BosulifBosutinib14$228,645
NinlaroIxazomib Citrate13$158,542
Imatinib Mesylate22$22,345
XareltoRivaroxaban12$16,080
Hydroxyurea110$3,127
Dexamethasone21$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$14,752$720,88237 claims
AstraZenecaCalquence$426$608,82444 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$53$571,37129 claims
Beigene USA, Inc.Brukinsa$41$567,73345 claims
AbbVieVenclexta$202$534,53743 claims
Incyte CorporationJakafi$83$361,77724 claims
GSKOjjaara$39$343,39912 claims
NovartisScemblix$487$246,03912 claims
PfizerBosulif$342$228,64514 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$884$158,54213 claims
Johnson & JohnsonXarelto$633$16,08012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →